Ironwood Pharmaceuticals Inc (IRWD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $799.61M
Last updated: Nov 17, 2026 at 11:06 AM ET
Ironwood Pharmaceuticals Inc (IRWD) Financials: Revenue, Profit and Cash Flow
Ironwood Pharmaceuticals reported revenue of $296.15M for the fiscal year ended Dec 31, 2025, down 15.7% from the year before. That year, net income was $24.02M with a net margin of 8.1%, operating cash flow was $127.04M and free cash flow was $127.01M. The quarter ended Sep 30, 2026 had revenue of $133.04M and net income of $59.84M.
Revenue and Margins
The operating margin was 33.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $273.96M, a compound annual rate of 0.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $296.15M | -15.7% | 100.0% | 33.3% | 8.1% |
| Dec 2024 | $351.41M | -20.6% | 100.0% | 26.5% | 0.3% |
| Dec 2023 | $442.74M | +7.8% | 100.0% | -213.5% | -233.0% |
| Dec 2022 | $410.60M | -0.8% | 100.0% | 61.0% | 42.6% |
| Dec 2021 | $413.75M | +6.2% | 100.0% | 56.1% | 127.7% |
| Dec 2020 | $389.52M | -9.1% | 99.2% | 36.7% | 27.3% |
| Dec 2019 | $428.41M | +23.6% | 94.4% | 28.0% | 5.0% |
| Dec 2018 | $346.64M | +16.2% | 90.6% | -43.5% | -81.5% |
| Dec 2017 | $298.28M | +8.9% | 93.6% | -5.2% | -39.2% |
| Dec 2016 | $273.96M | N/A | 99.3% | -18.9% | -29.8% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 2629.5% from the year before. In the quarter ended Sep 2026, net income rose 49.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296.15M | $351.41M | $442.74M | $410.60M | $413.75M | $389.52M | $428.41M | $346.64M | $298.28M | $273.96M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $3.14M | $23.88M | $32.75M | $19.10M | $1.87M |
| Gross profit | $296.15M | $351.41M | $442.74M | $410.60M | $413.75M | $386.39M | $404.54M | $313.89M | $279.18M | $272.09M |
| Research and development | $95.14M | $111.42M | $1.21B | $44.27M | $70.41M | $88.06M | $115.04M | $101.06M | $88.14M | $139.49M |
| Operating income | $98.50M | $93.12M | -$945.43M | $250.34M | $232.26M | $142.94M | $120.12M | -$150.67M | -$15.36M | -$51.87M |
| Net income | $24.02M | $880.00K | -$1.03B | $175.06M | $528.45M | $106.18M | $21.50M | -$282.37M | -$116.94M | -$81.71M |
| EBITDA | $100.58M | $95.78M | -$941.78M | $253.79M | $256.54M | $162.66M | $148.83M | -$130.01M | $10.01M | -$16.96M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133.04M | $113.04M | $106.51M | $47.71M | $122.06M | $85.24M | $41.14M | $90.55M | $91.59M | $94.40M | $74.88M | $117.55M |
| Gross profit | $133.04M | $113.04M | $106.51M | $47.71M | $122.06M | $85.24M | $41.14M | $90.55M | $91.59M | $94.40M | $74.88M | $117.55M |
| Operating income | $93.13M | $79.31M | $72.57M | $6.80M | $75.48M | $45.32M | -$29.11M | $31.49M | $25.64M | $24.98M | $11.02M | $37.59M |
| Net income | $59.84M | $51.29M | $40.77M | -$2.28M | $40.08M | $23.60M | -$37.39M | $2.26M | $3.65M | -$860.00K | -$4.16M | -$1.75M |
Balance Sheet
As of Dec 2025, total debt of $584.68M exceeded cash and equivalents by $369.22M. Shareholder equity was negative, at -$261.83M, as total liabilities of $658.74M exceeded total assets of $396.90M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $396.90M | $350.91M | $471.07M | $1.10B | $1.13B | $559.24M | $402.75M | $332.05M | $605.67M | $709.82M |
| Current assets | $274.18M | $182.37M | $233.29M | $780.63M | $745.23M | $495.84M | $306.85M | $266.44M | $311.60M | $380.18M |
| Cash and equivalents | $215.46M | $88.56M | $92.15M | $656.20M | $620.13M | $362.56M | $177.02M | $173.17M | $125.74M | $54.00M |
| Total liabilities | $658.74M | $652.24M | $817.37M | $448.14M | $521.02M | $496.60M | $496.00M | $528.42M | $595.83M | $643.11M |
| Short-term debt | $199.68M | $0 | $199.56M | $0 | $116.86M | $0 | $1.15M | $47.68M | $4.32M | $20.47M |
| Long-term debt | $385.00M | $583.99M | $498.31M | $396.25M | $337.33M | $430.26M | $407.99M | $366.14M | $396.09M | $366.49M |
| Shareholder equity | -$261.83M | -$301.33M | -$346.30M | $652.38M | $605.91M | $62.64M | -$93.25M | -$196.37M | $9.85M | $66.86M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $290.59M | $285.13M | $434.57M | $396.90M | $396.06M | $342.95M | $327.21M | $350.91M | $389.52M | $395.62M | $438.82M | $471.07M |
| Total liabilities | $387.79M | $446.97M | $651.71M | $658.74M | $660.22M | $651.11M | $661.27M | $652.24M | $700.85M | $717.35M | $769.34M | $817.37M |
| Cash and equivalents | $86.38M | $79.13M | $220.47M | $215.46M | $140.41M | $92.85M | $108.48M | $88.56M | $88.21M | $105.52M | $121.54M | $92.15M |
| Shareholder equity | -$97.19M | -$161.84M | -$217.14M | -$261.83M | -$264.16M | -$308.16M | -$334.05M | -$301.33M | -$311.33M | -$321.73M | -$330.52M | -$346.30M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $127.04M | $103.55M | $183.43M | $273.76M | $261.89M | $168.84M | $10.72M | -$70.88M | -$100.75M | -$25.93M |
| Capital expenditures | $34.00K | $142.00K | $273.00K | $136.00K | $265.00K | $1.84M | $7.19M | $351.00K | $2.80M | $4.21M |
| Free cash flow | $127.01M | $103.41M | $183.15M | $273.63M | $261.63M | $166.99M | $3.54M | -$71.23M | -$103.56M | -$30.14M |
| Dividends paid | N/A | N/A | $26.31M | $0 | $0 | N/A | N/A | N/A | $0 | $0 |
| Share repurchases | N/A | N/A | $0 | $126.39M | $24.13M | $0 | N/A | N/A | N/A | N/A |
| Investing cash flow | -$34.00K | -$142.00K | -$1.03B | -$136.00K | -$265.00K | -$1.84M | -$11.14M | $88.87M | $151.46M | -$177.67M |
| Financing cash flow | $216.00K | -$106.97M | $277.16M | -$237.55M | -$4.55M | $18.55M | -$1.19M | $30.07M | $19.84M | -$4.18M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $67.40M | $58.28M | $5.12M | $74.58M | $47.58M | -$15.07M | $19.95M | $15.21M | $9.88M | $33.47M | $44.98M | $35.83M |
| Capital expenditures | N/A | N/A | $0 | $1.00K | $2.00K | $2.00K | $31.00K | $16.00K | $16.00K | $58.00K | $68.00K | $211.00K |
| Free cash flow | N/A | N/A | $5.12M | $74.57M | $47.58M | -$15.07M | $19.92M | $15.20M | $9.87M | $33.41M | $44.92M | $35.62M |
Frequently Asked Questions About IRWD
What is Ironwood Pharmaceuticals' annual revenue?
Ironwood Pharmaceuticals reported revenue of $296.15M for the fiscal year ended Dec 31, 2025.
How fast is Ironwood Pharmaceuticals' revenue growing?
Revenue was down 15.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -10.3%.
Is Ironwood Pharmaceuticals profitable?
Yes. Ironwood Pharmaceuticals reported net income of $24.02M for the fiscal year ended Dec 31, 2025, with a net margin of 8.1%.
How much free cash flow does IRWD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $127.04M minus capital expenditures of $34.00K produced free cash flow of $127.01M.
How much debt does Ironwood Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $385.00M, short-term debt of $199.68M and cash and equivalents of $215.46M.
IRWD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors